ADiTx Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Mountain view, calif.--(business wire)--aditxt, inc. (“aditxt” or the “company”) (nasdaq: adtx), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("arrangement agreement") to acquire appili therapeutics inc. (tsx: apli; otcqx: aplif) (“appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. under the arrangement agr.

-- third consecutive year of phexxi net sales growth  -- -- total operating expense reduced 64% from 2022 levels  -- -- sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the phexxi launch -- san diego , march 27, 2024 /prnewswire/ -- the company behind phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator evofem biosciences, inc. (otcqb: evfm), today announced financial results for the fourth quarter and year ended december 31, 2023. highlights include: delivered $18.2 million of phexxi net product sales in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.

— medi-cal serves more than 15.4 million californians — — 7.4% improvement in phexxi rebate to take effect july 1, 2024 — san diego , march 20, 2024 /prnewswire/ -- commercial-stage women's health innovator evofem biosciences, inc. (otcqb: evfmd) today announced that it has successfully renegotiated the rebate for phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with medi-cal, the california state medicaid program. phexxi is the first and only locally-acting contraceptive gel approved by the fda.

-- new weight loss drugs like ozempic, wegovy and zepboundmay make oral birth control pills less effective at certain points -- san diego , march 7, 2024 /prnewswire/ -- use of glp-1 receptor agonists, or glp-1s, is skyrocketing in the united states, with more than nine million prescriptions for ozempic, wegovy, mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 zepbound weekly prescriptions hit 25,000 in december 2023, just one month after it was approved to treat obesity.2 these drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely. eli lilly's mounjaro and zepbound, which contain the same compound, clearly instruct prescribers to "advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.

Evofem delivers third consecutive year of phexxi net sales growth  total operating expense reduced more than 60% from 2022 levels  san diego , feb. 1, 2024 /prnewswire/ -- evofem biosciences, inc. (otcqb: evfm) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of phexxi® (lactic acid, citric acid, and potassium bitartrate), its hormone-free contraceptive gel, and the company's lowest total operating expenses since becoming a commercial stage company in 2020. achieved preliminary net product sales in the range of $18.1 to $18.3 million in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023.

Aditxt Inc's shares fell more than 20% in Tuesday premarket trading after the company announced the pricing of a $6 million private placement of shares and accompanying warrants. The Richmond, Virginia-based medical technologies company said it entered definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock at $4.85 per share and accompanying warrant, in a private placement priced at the market under Nasdaq rules.

Aditxt (NASDAQ: ADTX ) stock is rallying higher on Tuesday after the biotech company announced its plan to acquire Evofem Biosciences (OTCMKTS: EVFM ). According to a press release, Aditxt has agreed to acquire Evofem Biosciences in a deal worth $100 million.

The Aditxt (NASDAQ: ADTX) stock price jumped by more than 83% on Tuesday, making it one of the best performers in Wall Street. The shares surged to a high of $9.47, its highest point since October 19th.

Aditxt (NASDAQ: ADTX ) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why ADTX stock is up today.

Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023

RICHMOND, Va. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel in.

Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.

Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny stocks to watch this week. The post Best Penny Stocks To Buy?

Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.